ReportWire

Tag: Embargoed Feed – hidden

  • FREE Webinar for PM&R Career Path Guidance Hosted by AANEM

    FREE Webinar for PM&R Career Path Guidance Hosted by AANEM

    [ad_1]

    Newswise — Rochester, Minn. (Nov. 4 2022)- The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) invites medical students, physical medicine and rehabilitation (PM&R) residents, and early-career physiatrists to join experienced physicians at an interactive webinar to explore career options for physiatrists with a sub-specialty focus on neuromuscular (NM) and/or electrodiagnostic (EDX) medicine.

    “What a PM&R Physician Needs to Know About Considering a Career in NM or EDX Medicine,” will be held live on November 14, 2022, at 8:30 p.m. (EST). A recording will also be made public after the event. Attendees will learn about different pathways available so they can excel in NM and/or EDX medicine practice, the new AANEM Fellowship Match Portal, and how to leverage a foundation in physiatry with colleagues in neurology.

    Presentations will be given by a panel of experts, including Erik Ensrud, MD, University of Missouri-Columbia; Ileana Howard, MD, University of Washington; and more. Presentations will be followed by a live Q&A. Colin Franz, MD, PhD, a physician-scientist at Shirley Ryan AbilityLab, will moderate the webinar. “This session brings together a diverse group of PM&R specialists from across the country to share their insights on careers in electrodiagnostic and neuromuscular medicine,” he said. “When I was considering a neuromuscular fellowship, it was hard to find good advice from a PM&R perspective. It turns out there are multiple pathways to achieve a career with a strong focus on electrodiagnostic and/or neuromuscular medicine.”

    Registration: https://us02web.zoom.us/webinar/register/WN_lhvFTnA_TEW_JXxAx6oGgQ About American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Based in Rochester, MN, AANEM is the premier nonprofit membership association dedicated to the advancement of neuromuscular (NM), musculoskeletal, and electrodiagnostic (EDX) medicine.

    The organization and its members work to improve the quality of patient care and advance the science of NM diseases and EDX medicine by serving physicians and allied health professionals who care for those with muscle and nerve disorders.

    For more information about AANEM, visit aanem.org or Facebook, Twitter, LinkedIn, Instagram, and YouTube.

    ###

    [ad_2]

    American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)

    Source link

  • Shorter Course of Radiation Therapy Yields Comparable Results for Patients with Non-Metastatic Soft Tissue Sarcoma

    Shorter Course of Radiation Therapy Yields Comparable Results for Patients with Non-Metastatic Soft Tissue Sarcoma

    [ad_1]

    Newswise — HOUSTON – Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor control and no increased risk of major complications in wound healing, according to researchers at The University of Texas MD Anderson Cancer Center.

    Results from the study, led by Ashleigh Guadagnolo, M.D., professor of Radiation Oncology, were published today in The Lancet Oncology. Guadagnolo also presented results at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

    On the single-arm, non-randomized trial, patients received hypofractionated radiation therapy, consisting of higher daily radiation therapy doses per treatment over fewer days relative to conventional therapy. Thirty-one percent of patients developed major wound complications within 120 days of surgery, while local tumor control was 93% at two-year follow-up — both comparable to historically reported rates with the longer treatment course.

    “Our data indicate the three-week regimen offers patients a likely safe and effective alternative to the current standard of care with comparable outcomes in disease control and no increased risks of major wound complications,” Guadagnolo said. “We are excited by the current results of this study, which demonstrate the value of a hypofractionated approach to radiation therapy, which is more convenient for patients.”

    A major side effect of pre-operative radiation therapy in patients with non-metastatic STS is an increased risk of wound-healing complications after surgery. Patients have a heightened risk of needing a second operation for wound repair, extensive wound management and readmission to the hospital.  

    On the current study, no patients experienced a serious adverse event or a grade 3 acute skin toxicity while on the study. The 31% rate of major wound complications is comparable to the historically observed 35% rate in patients treated with the standard five-week regimen.

    “Research shows that patients receiving their treatment at cancer centers with sarcoma specialists have better survival and functional outcomes. Being able to shorten our patients’ treatment time from five to three weeks may improve care accessibility because patients would be able to reduce their time away from home if they do not live near a sarcoma specialty center,” Guadagnolo said.

    The trial enrolled a total of 120 patients over the age of 18 with non-metastatic STS who had not previously undergone radiation therapy. All patients had STS in the extremity or superficial trunk; 65% of participants had lower extremity tumors; 17% had upper extremity tumors and 18% had tumors in the trunk.

    All patients were treated with a three-week course of radiation consisting of 15 daily fractions of 2.85 Gray (Gy), totaling 42.75 Gy. The current standard dose is 50 Gy in 25 daily fractions, or a five-week course. Radiation therapy was followed by surgery four to eight weeks later. Researchers assessed major wound complications within 120 days of surgery among patients treated on the trial.

    Long-term side effects, oncologic and functional outcomes using the hypofractionated regimen still are being assessed.

    The research was supported by the National Cancer Institute (P30 CA016672). A full list of collaborating authors and their disclosures can be found with the full paper here.

    – 30 –

    [ad_2]

    University of Texas M. D. Anderson Cancer Center

    Source link

  • NIH’s Climate and Health Initiative tackles global health effects associated with a changing climate

    NIH’s Climate and Health Initiative tackles global health effects associated with a changing climate

    [ad_1]

    Newswise — Media Availability

    What: Leaders from the National Institutes of Health discuss the agency’s plan to address the risk to human health posed by a changing climate in a commentary published in The Lancet. As floods, hurricanes, tornados, wildfires, and heat waves become more extreme, the risk to human health grows, exacerbating existing health threats and creating new public health challenges around the world.

    The authors, a coalition of leaders at NIH, outline how the NIH Climate Change and Health Initiative is uniquely poised to lead and engage with communities and agencies globally to address the health effects associated with climate change.

    Article: The NIH Climate Change and Health Initiative and Strategic Framework: addressing the threat of climate change to health. The Lancet, November 2022. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02163-8/fulltext

    Who:  The following NIH leaders are available for interviews:

    Richard P. Woychik, Ph.D., director of the National Institute of Environmental Health Sciences. He is the lead author on The Lancet commentary, and the chair of the Executive Committee leading the NIH Climate Change and Health Initiative.

    Gary H. Gibbons, M.D., director of the National Heart, Lung, and Blood Institute.

    Roger I. Glass, M.D., Ph.D., director of the Fogarty International Center.

    Joshua A. Gordon, M.D., Ph.D., director of the National Institute of Mental Health

    Eliseo J. Pérez-Stable, M.D., director of the National Institute of Minority Health and Health Disparities.

     

    NOTE FOR REPORTERS: This commentary is under embargo until 7:30 p.m. EDT on Friday, Nov. 4, 2022.

    Comment pieces are written by experts in the field, and represent their own views, rather than necessarily the views of The Lancet or any Lancet specialty journal. Unlike Articles containing original research, not all Comments are externally peer reviewed.

     

    About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical and translational medical research, and is investigating the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov.

    [ad_2]

    National Institute of Environmental Health Sciences (NIEHS)

    Source link

  • Risks of kidney failure and death differ in Black and white veterans over time after chronic kidney disease onset

    Risks of kidney failure and death differ in Black and white veterans over time after chronic kidney disease onset

    [ad_1]

    Highlights

    • Among US veterans with chronic kidney disease (CKD), Black individuals had a higher risk of developing kidney failure compared with White veterans, and their risk was more pronounced in the early years after kidney disease onset.
    • The overall risk of death was similar in Black and White veterans, but Blacks had a higher risk early on, followed by a lower risk thereafter.
    • Results from the study will be presented at ASN Kidney Week 2022 November 3–November 6.

    Newswise — Orlando (November 4, 2022) — In an analysis of data on US veterans with chronic kidney disease (CKD), risks of kidney failure and death varied for Black compared with White veterans over time, with Black individuals being especially vulnerable in the early years after developing CKD. The research will be presented at ASN Kidney Week 2022 November 3–November 6.

    The study included 180,881 White and 32,187 Black veterans who developed CKD from 2003–2008 and were followed through 2018.

    During follow-up, the adjusted risk of kidney failure was 30% greater in Blacks than in Whites, but this difference was more pronounced over the early years of CKD onset (for example, a 38% greater risk in years 0–2) than at later years (only 8% greater risk in years 8–10). Despite an overall similar mortality risk after adjusting for major confounding factors, there was a greater risk of death for Blacks during the first 4 years of CKD onset, followed by a lower risk thereafter.

    These risk differences over time were consistent across subgroups, such as those with and without comorbidities including hypertension, diabetes, and cardiovascular diseases.

    “Black adults are particularly susceptible to kidney failure and death during the first several years of CKD onset. This result demands a stronger urgency for close evaluation in the earlier years of CKD to improve outcomes,” said corresponding author Guofen Yan, PhD, of the University of Virginia.

    Study: “Time-dependent risk differences in kidney failure and death between Black and White veterans following incident CKD”

    ASN Kidney Week 2022, the largest nephrology meeting of its kind, will provide a forum for nephrologists and other kidney health professionals to discuss the latest findings in research and engage in educational sessions related to advances in the care of patients with kidney diseases and related disorders.

    Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram.

     

    # # #

     

     

     

     

     

                           

    [ad_2]

    American Society of Nephrology (ASN)

    Source link

  • Long-Term Exposure to Air Pollution May Increase Kidney Disease Risk

    Long-Term Exposure to Air Pollution May Increase Kidney Disease Risk

    [ad_1]

    Highlights

    • Among adults with normal kidney function, exposure to higher concentrations of components of air pollution was linked with higher risks of later developing chronic kidney disease.
    • Compared with individuals with high genetic risk of developing kidney disease, those with high air pollution exposure and low genetic risk faced a higher risk of developing chronic kidney disease.  
    • Results from the study will be presented at ASN Kidney Week 2022 November 3–November 6.

    Newswise — Orlando (November 4, 2022) — Both genetic and environmental factors contribute to chronic kidney disease (CKD). New research assessed the interaction of air pollution and genetic factors on the development of CKD. The research will be presented at ASN Kidney Week 2022 November 3–November 6. 

    Investigators analyzed data from 350,994 participants without CKD at baseline in the UK Biobank. Exposure to higher concentrations of components of air pollution was linked with higher risks of developing CKD. Compared with individuals with high genetic risk of developing CKD, those with high air pollution exposure and low genetic risk faced a higher risk of developing CKD. 

    “Long-term exposure to air pollution may increase the risk of CKD, especially in those with low genetic risk,” the authors wrote.

    Study: “Air pollution, genetic factors, and the risk of incident chronic kidney disease: a prospective study of polygenic risk score analysis in the UK Biobank”

    ASN Kidney Week 2022, the largest nephrology meeting of its kind, will provide a forum for nephrologists and other kidney health professionals to discuss the latest findings in research and engage in educational sessions related to advances in the care of patients with kidney diseases and related disorders.

    Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram.

     

    # # #

     

     

     

     

     

                           

    [ad_2]

    American Society of Nephrology (ASN)

    Source link

  • DNA ‘Nanotransporters’ to treat cancer

    DNA ‘Nanotransporters’ to treat cancer

    [ad_1]

    Newswise — A team of Canadian researchers from Université de Montréal has designed and validated a new class of drug transporters made of DNA that are 20,000 times smaller than a human hair and that could improve how cancers and other diseases are treated

    Reported in a new study in Nature Communications, these molecular transporters can be chemically programmed to deliver optimal concentration of drugs, making them more efficient than current methods.

    Optimal dosing at all times: a medical challenge

    One of the key ways to successfully treat disease is to provide and maintain a therapeutic drug dosage throughout treatment. Sub-optimal therapeutic exposure reduces efficiency and typically leads to drug resistance, while overexposure increases side effects.

    Maintaining an optimal concentration of drugs in the blood remains a major challenge in modern medicine. Since most drugs undergo rapid degradation, patients are forced to (and often forget) to take multiple doses at regular intervals. And because each patient has a distinct pharmacokinetic profile, the drugs concentration in their blood varies significantly.

    Observing that only about 50 per cent of cancer patients get an optimal drug dosage during certain chemotherapy, UdeM Chemistry associate professor Alexis Vallée-Bélisle, an expert in bio-inspired nanotechnologies, started to explore how biological systems control and maintain the concentration of biomolecules.

    “We have found that living organisms employ protein transporters that are programmed to maintain precise concentration of key molecules such as thyroid hormones, and that the strength of the interaction between these transporters and their molecules dictates the precise concentration of the free molecule,” he said.

    This simple idea led Valléé-Belisle – who holds a Canada Research Chair in bioengineering and bionanotechnology – and his research team to start developing artificial drug transporters that mimic the natural effect of maintaining a precise concentration of a drug during treatment.

    UdeM PhD student Arnaud Desrosiers, the first author of the study, initially identified and developed two DNA transporters: one for quinine, an antimalarial, and the other for doxorubicin, a commonly used drug for treating breast cancer and leukemia.

    He then demonstrated that these artificial transporters could be readily programmed to deliver and maintain any specific concentration of drug.

    “More interestingly, we also found that these nanotransporters could also be employed as a drug reservoir to prolong the effect of the drug and minimize its dosage during treatment,” said  Desrosiers.

    “Another impressive feature of these nanotransporters,” he added, “is that they can be directed to specific parts of the body where the drug is most needed – and that, in principle, should reduce most side effects.”

    Nanotreated mice: reduced cardiotoxicity

    To demonstrate the effectiveness of these nanotransporters, the researchers teamed up with Jeanne Leblond-Chain, a pharmacist at Université de Bordeaux, in France; Luc DesGroseillers, a biochemist at UdeM; Jérémie Berdugo, a pathologist at UdeM; Céline Fiset, a pharmacist at the Montreal Heart Institute; and Vincent De Guire, a clinical biochemist at the UdeM-affiliated Maisonneuve-Rosemont Hospital.

    Using the new drug transporter developed for doxorubicin, the team demonstrated that a specific drug-transporter formulation allows doxorubicin to be maintained in the blood and drastically reduces its diffusion towards key organs such as the heart, lungs and pancreas.

    In mice treated with this formulation, doxorubicin was maintained 18 times longer in the blood and cardiotoxicity was reduced as well, keeping the mice more healthy as evidenced by their normal weight gain. 

    “Another great property of our nanotransporters is their high versatility,” said Vallée-Bélisle.

    “For now, we have demonstrated the working principle of these nanotransporters for two different drugs. But thanks to the high programmability of DNA and protein chemistries, one can now design these transporters to precisely deliver a wide range of threrapeutic molecules.”

    And, he added, “additionally, these transporters could also be combined with human-designed liposomic transporters that are now being employed to deliver drugs at various rates.”

    A clinical study for blood cancers?

    The researchers are now eager to validate the clinical efficiency of their discovery. Since their doxorubicin nanotransporter is programmed to optimally maintain the drug in blood circulation, it could be deal to treat blood cancers, they believe.

    “We envision that similar nanotransporters may also be developed to deliver drugs to other specific locations in the body and maximize the presence of the drug at tumor sites,” said Vallée-Bélisle. “This would drastically improve the efficiency of drugs as well as decrease their side effects.”

    [ad_2]

    Universite de Montreal

    Source link

  • New Tool for Estimating People’s Total Exposure to Potentially Harmful Chemicals Is Developed

    New Tool for Estimating People’s Total Exposure to Potentially Harmful Chemicals Is Developed

    [ad_1]

    Newswise — New York, NY (November 2, 2022) – A novel metric that estimates our “burden,” or cumulative exposure, to a family of thousands of synthetic chemicals that we encounter in everyday life with potentially adverse health impacts, has been created by a team of researchers at Mount Sinai.

    In a paper published in Environmental Health Perspectives, the team reported that its sophisticated tool could have distinct advantages for epidemiologists and researchers who routinely measure exposure levels to this class of chemicals, known as PFAS (per- and polyfluoroalkyl substances), which have been associated with high cholesterol, liver damage, thyroid disease, and hormone disorders.

    “There are few existing methods to quantify total exposure burden of individuals to mixtures of PFAS chemicals that are found in our everyday lives,” says lead author Shelley Liu, PhD, Assistant Professor in the Center for Biostatistics, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai. “For the first time we’ve developed a PFAS burden calculator that takes into account patterns of exposure to many chemicals within the PFAS family, and not just individual chemical concentrations which current methods are focused on. As a result, this robust tool could be extremely useful for biomonitoring by regulatory agencies, and for disease and health risk assessment.”

    PFAS is a class of more than 5,000 chemicals whose fluorine-carbon bond gives them the ability to repel oil and water. That construct has made them an integral part of a growing number of industrial applications and consumer products in recent decades, such as stain and water repellents, Teflon nonstick pans, paints, cleaners, and food packaging. Moreover, PFAS chemicals do not disintegrate in the environment or in our bodies. Instead, they accumulate in our surroundings and in our blood, kidneys, and liver, as underscored by a Centers for Disease Control and Prevention study in 2007 that found PFAS could be detected in the blood of 98 percent of the U.S. population.

    Mount Sinai researchers used national biomonitoring data from the National Health and Nutrition Examination Survey to develop their exposure burden score using item response theory. Item response theory was developed in the educational testing literature to score standardized tests, and Mount Sinai researchers are the first to use it in environmental epidemiology to develop an exposure burden score, highlighted by this transdisciplinary investigation. Specifically, they used serum concentrations from eight common PFAS chemicals taken from adults and children. By combining a participant’s core biomarker concentrations with their much broader “exposure pattern,” that is, their relative exposure to other PFAS biomarkers within the entire chemical class, researchers were able to estimate a cumulative or summary PFAS exposure burden. This statistical methodology can be accessed by other researchers and epidemiologists by simply plugging their data sets into the PFAS burden calculator, which is available online.

    The benefits are significant. “We found our method enables comparisons of exposure burden to chemical mixtures across studies even if they do not measure the same set of chemicals, which supports harmonization across studies and consortia,” explains Dr. Liu, whose research is heavily focused on environmental health through latent variable modeling and longitudinal data analysis. Moreover, the calculator offers a straightforward way to include exposure biomarkers with low detection frequencies, and to reduce exposure measurement errors by considering both a participant’s concentrations and their exposure patterns to estimate exposure burden to chemical mixtures.

    “By capturing individual biomarker variability, we’re essentially holding the exposure metric constant so it can be used for a variety of applications,” says Dr. Liu. “These could include, for example, looking across populations to determine if there are differences in exposure burden across racial/ethnic or socioeconomic strata, or if exposure burdens are the same between people in the United States or Canada. Or looking across physiological systems and health outcomes—such as cardiometabolic, hormonal, and immune—to see which are most perturbed by exposure to PFAS chemicals. This range of applications takes us well beyond anything currently available to the field of population health.” 

    Other co-authors in the study were from the Johns Hopkins Bloomberg School of Public Health, the Department of Psychology at Fordham University, and the Stroud Center at Columbia University. Dr. Liu’s research is supported by grants from the National Institute of Child Health and Human Development (K25HD104918) and National Institute of Environmental Health Sciences (R03ES033374).

     

    About the Mount Sinai Health System

    Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

    Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report‘s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report‘s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

    For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.

     

    [ad_2]

    Mount Sinai Health System

    Source link

  • November 2022 Issue of Neurosurgical Focus: “Evolution of Radiation Therapy Technique”

    November 2022 Issue of Neurosurgical Focus: “Evolution of Radiation Therapy Technique”

    [ad_1]

    Newswise — November 2022 Issue of Neurosurgical Focus: “Evolution of Radiation Therapy Technique”

    Rolling Meadows, IL (November 1, 2022). The November issue of Neurosurgical Focus (Vol. 53, No. 5 [https://thejns.org/focus/view/journals/neurosurg-focus/53/5/neurosurg-focus.53.issue-5.xml]) presents one editorial and 10 articles on the history and development of radiation therapy in neurosurgical treatment.

    Topic Editors: Arjun Sahgal, Jason P. Sheehan, Ajay Niranjan, Lola B. Chambless, Lijun Ma, and Daniel M. Trifiletti

    The Topic Editors of this issue note that, “Radiation technology has undergone dramatic changes over the past 3 decades.” Therefore, this issue of Neurosurgical Focus aims to “further our understanding of stereotactic radiosurgery and stereotactic radiotherapy for primary brain tumors and functional conditions, as well as new developments for patients with brain metastases.”

    Contents of the November issue: 

    • “Introduction. Evolution of radiation therapy techniques” by Arjun Sahgal et al.
    • “Stereotactic radiosurgery for recurrent pediatric brain tumors: clinical outcomes and toxicity” by Elyn Wang et al.
    • “Stereotactic radiosurgery for trigeminal neuralgia secondary to tumor: a single-institution retrospective series” by Jennifer C. Hall et al.
    • “CyberKnife radiosurgery for trigeminal neuralgia: a retrospective review of 168 cases” by Albert Guillemette et al.
    • “Adjuvant stereotactic radiosurgery with or without postoperative fractionated radiation therapy in adults with skull base chordomas: a systematic review” by Othman Bin-Alamer et al.
    • “Outcomes following stereotactic radiosurgery for foramen magnum meningiomas: a single-center experience and systematic review of the literature” by Constantine L. Karras et al.
    • “Risk factors for peritumoral edema after radiosurgery for intracranial benign meningiomas: a long-term follow-up in a single institution” by Sheng-Han Huang et al.
    • “Neoadjuvant stereotactic radiosurgery for brain metastases: a new paradigm” by Yuping Derek Li et al.
    • “Stereotactic radiosurgery and resection for treatment of multiple brain metastases: a systematic review and analysis” by Uma V. Mahajan et al.
    • “A quantitative and comparative evaluation of stereotactic spine radiosurgery local control: proposing a consistent measurement methodology” by Ran Harel et al.
    • “Editorial. Assessing treatment response following stereotactic body
    • radiotherapy for spinal metastases” by Steven G. Roth and Lola B. Chambless
    • “The role of radiation therapy in the treatment of spine metastases from hepatocellular carcinoma: a systematic review and meta-analysis” by Gianluca Ferini et al.

     Please join us in reading this month’s issue of Neurosurgical Focus.

     ***

     ###

     

    The global leader for cutting-edge neurosurgery research since 1944, the Journal of Neurosurgery (www.thejns.org) is the official journal of the American Association of Neurological Surgeons (AANS) representing over 12,000 members worldwide (www.AANS.org).

    [ad_2]

    Journal of Neurosurgery

    Source link

  • It’s Not the Heat, It’s the Humidity: Water Loss Hurts Bees Most in the Desert

    It’s Not the Heat, It’s the Humidity: Water Loss Hurts Bees Most in the Desert

    [ad_1]

    Newswise — (San Diego) October 29, 2022—Digger bees lose large amounts of water during flight, which compromises their activity period and survival in the desert heat. Researchers from Arizona State University will present their work this week at the American Physiological Society (APS) Intersociety Meeting in Comparative Physiology: From Organism to Omics in an Uncertain World conference in San Diego. 

    “Water loss appears to be a critical problem for male digger bees. Climate change will very likely challenge their important ecological functions.” —Meredith Johnson

    Climate change plays a role in the physiological evolution and survival of animals of all sizes. Desert animals, already acclimated to high temperatures, use evaporative heat loss to help prevent overheating. However, the sometimes-limited ability to replenish water loss means the danger of dehydration is a challenge for desert animals, including the Sonoran Desert digger bee.

    Bees are an integral part of the ecosystem due to their ability to pollinate—more than 80% of flowering plants rely on insect pollinators. When bees become unable to pollinate sufficiently—due to lack of food or other changes in their environment—plant biodiversity decreases and plant-eating animals are affected. A large percentage of food crops, including fruits, nuts and vegetables, also depend on pollination. Researchers explored the effects of heat, water stress and food availability on male digger bees in the Arizona Uplands, a region of the Sonoran Desert.

    During the study, air temperatures increased from around 66 degrees F in the early morning—when the bees began to fly to a mating site—to about 100 degrees at midday, when they typically stop flying for the day. In addition, no plants were in bloom at the study site to provide nectar for the bees to drink at the time of the study. Marking techniques used by the research team suggest that the bees survive for about a week, which means they are finding nectar somewhere in the desert. Researchers think the bees may be traveling for some distance during the later—and hotter—part of the day to find food.

    The researchers also examined the bees’ body temperature and body water content throughout the day. The hottest body temperature measurement was approximately 111 degrees F. Digger bees can withstand body temperatures around 125 degrees during flight, suggesting that overheating is not why the bees stopped flying before midday, explained Meredith Johnson, a doctoral candidate at Arizona State University and first author of the study.

    Water loss is a bigger problem for the insects. “These bees lose 17% of their body water content per hour, with the amount slightly increasing as the air temperature [rises],” Johnson said. “Loss of about 50% of total body water content is lethal, suggesting that these bees can maximally fly for about three hours.”

    The flying time constraint is important to note, as typically bees need to fly for six or seven hours each day searching for mating opportunities. Without sufficient time to mate, the bee population will shrink in the future.

    “Water loss appears to be a most critical problem for male digger bees. Climate change will very likely challenge their important ecological functions,” Johnson said.

    Physiology is a broad area of scientific inquiry that focuses on how molecules, cells, tissues and organs function in health and disease. The American Physiological Society connects a global, multidisciplinary community of more than 10,000 biomedical scientists and educators as part of its mission to advance scientific discovery, understand life and improve health. The Society drives collaboration and spotlights scientific discoveries through its 16 scholarly journals and programming that support researchers and educators in their work. 

     

    [ad_2]

    American Physiological Society (APS)

    Source link

  • Math Model Shows Climate Change Puts Rainforest Animal’s Survival in Jeopardy

    Math Model Shows Climate Change Puts Rainforest Animal’s Survival in Jeopardy

    [ad_1]

    Newswise — (San Diego) October 29, 2022—A South American marsupial with ties to an ancient line of animals may go extinct in the next half-century due to warming temperatures. Researchers from the Universidad Austral de Chile will present a mathematical model of the monito del monte’s survival predictions this week at the American Physiological Society (APS) Intersociety Meeting in Comparative Physiology: From Organism to Omics in an Uncertain World conference in San Diego. 

    The monito del monte, native to the rainforests of South America, is a marsupial in the relict family Microbiotheriidae. These tiny animals typically weigh about 20 grams (0.7 ounce) and measure around 3 to 5 inches long. Monitos reproduce and prepare for winter hibernation during the summer. Preparation includes eating as much as possible—including fruit, insects, small birds and other dead animals—to store as body fat. Researchers estimate that monitos need to have fat reserves that are almost twice their body weight to survive the winter.

    Climate change predictions show that ambient temperatures in coastal Chile will increase an estimated 36.5 degrees F over the next 50 years. This will have a large impact on the ability of the monito population to survive the winter. The warmer temperatures will cause the animals to come out of hibernation earlier than usual, and they will be unable to find food during the winter, explained Roberto Nespolo Rossi, PhD, first author of the study. Nespolo and his research team developed a mathematical model to estimate survival rates for the monito population in the advent of global warming.

    The mathematical model uses an algebraic formula to connect days of winter survival with the ambient temperature. The calculations are based on the assumption that all of the monitos’ daily energy expenditure during hibernation comes from the fat stores they have accumulated during the warmer months.

     

    Energy content of fat (kilojoule per gram) X Fat stores (grams)

    ­­­­­_______________________________________________________ 

    Daily energy expenditure (kilojoule per day)

    The model “is one of the few predictive models built on physiological parameters, so it can be applied to other hibernators, for which there is plenty of physiological data,” Nespolo said. “Our predictions for 50 years … indicate that most coastal populations [of monitos] will go extinct,” he added. This is especially important because the monito, sometimes referred to as a “living fossil,” is the last living relative of the ancient marsupial order Microbiotheria.

    Physiology is a broad area of scientific inquiry that focuses on how molecules, cells, tissues and organs function in health and disease. The American Physiological Society connects a global, multidisciplinary community of more than 10,000 biomedical scientists and educators as part of its mission to advance scientific discovery, understand life and improve health. The Society drives collaboration and spotlights scientific discoveries through its 16 scholarly journals and programming that support researchers and educators in their work. 

    [ad_2]

    American Physiological Society (APS)

    Source link

  • Food Security Harmed by Warming Ocean, Accelerating Fish Development

    Food Security Harmed by Warming Ocean, Accelerating Fish Development

    [ad_1]

    Newswise — (San Diego) October 29, 2022— Higher temperatures spurred by worsening climate change increased the growth rate of fish and consumption of their yolk sac—a structure that provides an embryo with food and helps develop important structures, such as blood cells. In addition, higher temperatures boosted fish mortality rates and led to faster depletion of their yolk sac, according to researchers at Scripps Institution of Oceanography at the University of California San Diego. The findings will be presented this week at the American Physiological Society (APS) Intersociety Meeting in Comparative Physiology: From Organism to Omics in an Uncertain World conference in San Diego. 

    Ocean temperatures are predicted to rise as carbon monoxide gas accumulates due to climate change. To determine the impact on larval white seabass, researchers sampled fish reared at 18–23 degrees Celsius throughout development from birth to six days old. With this process, they were hoping to differentiate the effects of temperature and time. They estimated growth and development rates by examining images obtained under a light microscope, among other methods.

    These findings are important because it helps inform fish population predictions in the face of climate change. The fishing industry is an important link in the U.S. food supply chain. Predicting growth rates and population structures of white seabass, a commercially and recreationally significant population in California, is critically important to help ensure food security.

    “Our results suggest that larval fish recruitment could swing to either extremity as a result of ocean warming,” said Ria Bhabu, co-author of the study and a student at the University of California San Diego. 

    Physiology is a broad area of scientific inquiry that focuses on how molecules, cells, tissues and organs function in health and disease. The American Physiological Society connects a global, multidisciplinary community of more than 10,000 biomedical scientists and educators as part of its mission to advance scientific discovery, understand life and improve health. The Society drives collaboration and spotlights scientific discoveries through its 16 scholarly journals and programming that support researchers and educators in their work. 

    [ad_2]

    American Physiological Society (APS)

    Source link

  • Climate Change Negatively Affecting School Sharks

    Climate Change Negatively Affecting School Sharks

    [ad_1]

    Newswise — (San Diego) October 29, 2022— Preliminary research data suggest warmer temperatures and increased salt levels might have negative effects on the behavior and physiology of school sharks. A clear indicator of physiological changes is higher levels of stress markers such as glucose and lactate concentrations in the blood. Researchers also noted behavior changes according to the warmer and saltier the environment is and the more time school sharks spend resting. School sharks are usually constantly swimming. A break in their usual activity means they might be too stressed to find food or escape predators. The findings will be presented this week at the American Physiological Society (APS) Intersociety Meeting in Comparative Physiology: From Organism to Omics in an Uncertain World conference in San Diego. 

    Researchers also examined the response of school sharks to increases in temperatures and salinity levels based on neonatal and juvenile (one year old and older) stage. The findings show newborns were more tolerant of some of the environmental changes than juveniles. This suggests neonates might have a special ability at birth to inhabit coastal waterways where freshwater mixes with salt water before migrating into deeper waters as juveniles. 

    The shallow water home of school sharks is constantly fluctuating, but this natural variation is being exacerbated due to the rapid pace of climate change. As a result, researchers through this study were seeking to determine “if this endangered species will be able to continue using these protected, resource-rich waters, or if they will be forced out into the ocean, which may have major ecological implications for the survival of the species.” They specifically wanted to know if the nursery ground in southeast Tasmania will remain a viable area for school shark pups in the coming years. To reach their conclusion, researchers evaluated the physiology and biochemistry of neonatal and juvenile sharks. 

    “Hopefully, these findings will be able to guide or inform regulations that can improve shark health,” said Katherine Ollerhead, a PhD candidate at the University of Tasmania in Australia and co-author of the study. 

    Physiology is a broad area of scientific inquiry that focuses on how molecules, cells, tissues and organs function in health and disease. The American Physiological Society connects a global, multidisciplinary community of more than 10,000 biomedical scientists and educators as part of its mission to advance scientific discovery, understand life and improve health. The Society drives collaboration and spotlights scientific discoveries through its 16 scholarly journals and programming that support researchers and educators in their work. 

    [ad_2]

    American Physiological Society (APS)

    Source link

  • Study assesses symptom trajectories and outcomes in patients with kidney disease

    Study assesses symptom trajectories and outcomes in patients with kidney disease

    [ad_1]

    Highlights

    • Among individuals with varying levels of chronic kidney disease who were not on dialysis, the prevalence of individual symptoms ranged from 24% (chest pain) to 83% (fatigue), and 98% of participants reported at least one symptom.
    • Patients categorized as having a “Worse symptom score and worsening trajectory” of symptoms had higher risks of later needing dialysis and of dying before dialysis initiation.

    Newswise — Washington, DC (October 28, 2022) — When individuals with varying degrees of chronic kidney disease who were not on dialysis answered annual questionnaires about their symptoms, researchers found that one-third could be categorized as having a “Worse symptom score and worsening trajectory” of symptoms. As reported in CJASN, these patients had especially high risks of later needing dialysis and of dying before dialysis initiation.

    For the study, Moustapha Faye, MD (CHRU Nancy, Université Cheikh Anta Diop de Dakar) and his colleagues, investigators of the CKD-REIN cohort study, assessed symptoms annually using the Kidney Disease Quality of Life-36 questionnaire that was completed by 2,787 adults in France with CKD who were not on dialysis.

    The prevalence of each symptom ranged from 24% (chest pain) to 83% (fatigue), and 98% of participants reported at least one symptom. After a median follow-up of 5.3 years, 690 participants initiated kidney replacement therapy (KRT) such as dialysis, and 490 died before KRT. The team identified two profiles of symptom trajectories: a “Worse symptom score and worsening trajectory” in 31% of participants, characterized by a low initial symptom score that worsened more than 10 points (on a scale of 0–100) over time, and a “Better symptom score and stable trajectory” in 69% of participants, characterized by a high initial score that remained stable over time.

    Participants in the “Worse symptom score and worsening trajectory” category had more risk factors for CKD progression at baseline, worse quality of life, and a higher risk of KRT and death before KRT than other participants.

    “In addition to the already existing classifications of CKD, it is possible to actively monitor symptoms and classify patients according to their progression. This monitoring should involve practitioners and patients,” said Dr. Faye. “This active symptom tracking will allow early therapeutic interventions to be planned to help manage different symptoms.”

    An accompanying editorial notes that “in addition to disease management, Faye et al. provide further evidence of the need to care for the unpleasant symptoms that cause suffering and affect the well-being of patients with advanced CKD”

    Additional study authors include Karine Legrand, PhD; Lisa Le Gall; Karen Leffondre, PhD; Abdou Y. Omorou, MD, PhD; Natalia Alencar de Pinho, PhD; Christian Combe, MD, PhD; Denis Fouque, MD, PhD; Christian Jacquelinet, PhD; Maurice Laville, PhD; Sophie Liabeuf, PhD; Ziad A Massy, MD, PhD; Elodie Speyer, PhD; Roberto Pecoits Filho, PhD; Bénédicte Stengel, MD, PhD; Luc Frimat, MD, PhD; and Carole Ayav, MD; and the CKD-REIN Study Group.

    Disclosures: The authors reported no financial disclosures.

    The article, titled “Five-Year Symptom Trajectories in Non-Dialysis Dependent Chronic Kidney Disease Patients,” will appear online at http://cjasn.asnjournals.org/ on October 28, 2022, doi: 10.2215/CJN.06140522.

    The editorial, titled “Can We Turn the Symptom Curve? Symptom Trajectories and Outcomes among Patients with CKD,” will appear online at http://cjasn.asnjournals.org/ on October 28, 2022, doi: 10.2215/CJN.11240922. 

    The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

    About ASN Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram.

     

     

    # # #

    [ad_2]

    American Society of Nephrology (ASN)

    Source link

  • Real-time space readings of ‘super emitter’ power plants leaves nowhere to hide for big polluters

    Real-time space readings of ‘super emitter’ power plants leaves nowhere to hide for big polluters

    [ad_1]

    Summary: Under the Paris Agreement, countries will need to track greenhouse gas emissions at the level of individual ‘super-emitters’, such as power plants, in close-to real time. Researchers show for the first time that this is already possible with data from existing satellites and instruments like NASA’s OCO-2 and OCO-3 (attached to the International Space Station), both designed to measure emissions at much larger spatial scales. This proof-of-principle indicates that the EU’s ‘CO2M’ pair of satellites, planned for 2025 or 2026, with a joint coverage a hundred times greater than OCO-2 and OCO-3, should be able to deliver on future needs.  

    Newswise — Countries signed up to the 2015 Paris Agreement have committed themselves to keep the rise in average global temperature ‘well below’ 2 °C. Every five years, they are to issue so-called ‘nationally determined contributions’ (NDCs), describing their actions to reduce greenhouse gas (GHG) emissions and adapt to climate change impacts. 

    Countries will thus need to track their carbon emissions, not only at a national level, but also at the scale of individual ‘super-emitters’ such as power plants, megacities, refineries, and giant factories — together responsible for nearly half of humanity’s total output of GHGs.

    In late 2025 or 2026, the EU plans to launch its ‘CO2M’ (Copernicus Anthropogenic CO2 Monitoring Mission) pair of satellites, whose job will be to help with this. 

    Important proof-of-principle for CO2M

    But now, scientists have shown that such tracking-at-the-source is already possible, even with existing satellites, for ‘super-emitters’ like the Bełchatów power plant in Poland. For this proof-of-principle, they used five years of measurements from NASA’s satellite ‘Orbiting Carbon Observatory 2’ (OCO-2; launched in 2014) and the instrument OCO-3, attached since 2019 to the International Space Station (ISS).

    This success is an important achievement, as the OCO missions were designed to measure carbon emissions at much larger spatial scales.

    “Here we show for the first time that it’s already possible to measure changes in CO2 emissions from a large power plant, with observations from existing CO2-tracking satellites,” said Dr Ray Nassar, an atmospheric scientist at Environment and Climate Change Canada, Toronto, and the study’s first author, published in Frontiers in Remote Sensing.

    Largest power plant in Europe 

    The Bełchatów lignite-fired (brown coal) power plant is the largest thermal power station in Europe and the fifth largest in the world. Here, units are sometimes decommissioned and new ones put in service, while more often, units shut down temporarily for maintenance. To be of use, satellites and instruments like OCO-2 and OCO-3 should immediately detect changes in CO2 emissions due to these changes in operation — and here, Nassar and colleagues show for the first time that they can.

    CO2 is emitted by the 300 meter-high stacks at Bełchatów and carried by the wind in the form of an invisible plume, approximately 10-50 km long and 550 meters above Earth. OCO-2, which orbits the Earth at an altitude of 705 km, passes every 16 days close by or directly over Bełchatów. OCO-3 orbits at an altitude of 420 km and passes over or near Bełchatów more frequently. OCO-3 has the added capability to scan back and forth across a region, giving better local coverage or a wider view.

    Not every flyby or overpass is suitable

    Satellites can assess the CO2 ‘enhancement’ — extra CO2 emitted by a source — only in the absence of clouds and when the plume doesn’t pass over large water bodies or mountains. They measure ‘XCO2’, the average CO2 concentration across a column directly below, subtracting the current background value (locally, on average 415 ppm) around the plume. 

    Together, OCO-2 and OCO-3 yielded 10 suitable datasets about the CO2 plume above Bełchatów between 2017 and 2022.

    Excellent agreement between observed and predicted data 

    The researchers compared the measurements from space to estimates for Bełchatów’s emissions, based on its known daily power generation output. The measurements turned out to closely track the daily predictions. This proves that even today, existing satellites can track emissions in close-to-real time for installations like Bełchatów. For example, OCO-2 detected a pronounced but transient dip in emissions from Bełchatów between June and September 2021, due to shutdowns for maintenance.

    All clear for CO2M 

    The results are promising: they indicate that CO2M, with a joint spatial coverage about a hundred times greater than OCO-2 and OCO-3, will be able to deliver on future needs. 

    “The capacity to get the most precise information about CO2 emissions from ‘super-emitters’, such as the Bełchatów power plant, across the globe will boost transparency in carbon accounting and hopefully, it will ultimately help to reduce these emissions,” said Nassar.

    “This future capacity will lead to improved CO2 emission information at the scale of countries, cities or individual facilities, enhancing transparency under the Paris Agreement and supporting efforts to reduce emissions causing climate change.”

    ###    

    For editors / news media:

    Please link to the open access original research article “Tracking CO2 emission reductions from space: A case study at Europe’s largest fossil fuel power plant” in Frontiers in Remote Sensing in your reporting:

    https://www.frontiersin.org/articles/10.3389/frsen.2022.1028240/full

     

     

    [ad_2]

    Frontiers

    Source link

  • Outpatient Visits Are Critical to Success of Treating Opioid-Use Disorder, Researchers Find

    Outpatient Visits Are Critical to Success of Treating Opioid-Use Disorder, Researchers Find

    [ad_1]

    Newswise — People with opioid-use disorder who enter treatment are at risk for relapse, overdose or death if they engage in less than two outpatient visits in their first month of care, according to a study coauthored by Rutgers researchers.

    The study, published in The American Journal of Psychiatry, examined the likelihood of patients continuing treatment for opioid-use disorder during their first month in care based on how often they engaged in outpatient visits or other professional services.

    “Engagement in outpatient visits or professional services appears to be a necessary condition for adequate care retention,” said study coauthor Stephen Crystal, the director of the Center for Health Services Research at the Rutgers Institute for Health, Health Care Policy and Aging Research and Distinguished Research Professor at the Rutgers School of Social Work. “Monitoring this engagement may help identify and address barriers and disparities in outcomes.”

    Starting an individual on medication for opioid-use disorder and then retaining them in professional care are two evidence-based interventions for reducing overdoses, according to the National Academies of Sciences, Engineering and Medicine. Researchers said patients participating in outpatient visits during treatment can be a measure of success for care retention, but there is a need to assess how this measure applies specifically to individuals with opioid-use disorder who are receiving medication, such as buprenorphine, as part of treatment.

    Using data reported between 2011 and 2019 from a multisite buprenorphine clinic throughout eight states, researchers examined the relationship between participating in outpatient visits and care retention in nearly 20,000 individuals. The patients were predominately male and non-Hispanic, which is broadly representative of people nationwide who are using buprenorphine for opioid use disorder treatment, according to prior research from study authors.

    Researchers found that nearly half of patients who participated in multiple outpatient visits in their first month of care remained in treatment for a minimum of six months, whereas 2.9 percent of patients who didn’t participate in multiple visits remained in treatment after six months.

    “This finding is critically meaningful and could guide intervention development to prioritize stabilization of high-risk patients early in treatment,” said Arthur Robin Williams, lead author of the study and an assistant professor at Columbia University Department of Psychiatry. “Without early engagement, the great majority of patients will be lost to relapse and possible death.”

    The study’s findings align with the priorities of organizations such as the Substance Abuse and Mental Health Services Administration, which support care coordination and peer navigation services early in treatment to help stabilize patients who otherwise might be lost to follow up. 

    “Many of these services are not currently reimbursable by payers, so insurance plans need to create bundled rates to be more innovative,” Williams said.

    More research is needed to identify patients at the greatest risk for overdose, said the researchers, adding that further research can demonstrate the importance of milestones in opioid-use treatment to develop care-performance measures.

     

    ABOUT RUTGERS INSTITUTE FOR HEALTH, HEALTH CARE POLICY AND AGING RESEARCH 

    Rutgers Institute for Health, Health Care Policy and Aging Research advances health and well-being through meaningful, rigorous and impactful research in the critical areas of behavioral health, health services, health disparities, health policy, health economics, pharmacoepidemiology, and aging research. 

    Since its 1985 founding, the Institute has become nationally renowned for interdisciplinary and translational research. The Institute’s 57,000 square foot facilities are home to six members elected to the National Academy of Medicine and 200 members representing over 30 schools, institutes, and units with adjunct members from 29 national and international universities.

    [ad_2]

    Institute for Health, Health Care Policy and Aging Research at Rutgers University

    Source link

  • Green eyeglasses reduce pain-related anxiety in fibromyalgia patients, study shows

    Green eyeglasses reduce pain-related anxiety in fibromyalgia patients, study shows

    [ad_1]

    Newswise — NEW ORLEANS — Wearing special green eyeglasses for several hours a day reduces pain-related anxiety and may help decrease the need for opioids to manage severe pain in fibromyalgia patients and possibly others who experience chronic pain, according to a study being presented at the ANESTHESIOLOGY® 2022 annual meeting.

    “Our research found that certain wavelengths of green light stimulate the pathways in the brain that help manage pain,” said Padma Gulur, M.D., lead author of the study and executive vice chair of Duke Anesthesiology and Duke Health, Chapel Hill, North Carolina. “There is an urgent need for additional treatments to reduce the use of opioids among patients with fibromyalgia and other types of chronic pain, and green eyeglasses could provide an easy-to-use, non-drug option.”

    Few alternatives to opioids — especially non-drug options — exist for patients with severe and chronic pain conditions such as fibromyalgia, which causes pain all over the body. Fibromyalgia affects about 4 million U.S. adults, according to the Centers for Disease Control and Prevention. 

    Pain and anxiety share similar biological mechanisms. Additionally, fear of pain exacerbates anxiety, often leading to increased opioid use, said Dr. Gulur. 

    The researchers studied 34 fibromyalgia patients who were randomized to wear various shades of eyeglasses four hours a day for two weeks: 10 patients wore blue eyeglasses, 12 wore clear eyeglasses and 12 wore green eyeglasses. Patients who wore green eyeglasses were four times more likely to have reduced anxiety than those in the other groups, which saw no reduction in anxiety. 

    “We found that although their pain scores remained the same, those who wore the green eyeglasses used fewer opioids, demonstrating that their pain was adequately controlled,” said Dr. Gulur. “We would recommend the green eyeglasses treatment for those with fibromyalgia and are studying patients with other chronic pain conditions to determine if it would be beneficial.”  

    The eyeglasses are specially formulated to filter a specific wavelength on the green light spectrum, said Dr. Gulur. She noted that most patients who wore the green eyeglasses reported feeling better and asked to keep wearing them.

     

    THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

    Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 55,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves. 

    For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/MadeforThisMoment. Join the ANESTHESIOLOGY® 2022 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES22.


    # # #

    [ad_2]

    American Society of Anesthesiologists (ASA)

    Source link

  • Cannabis use increases pain after surgery, study shows

    Cannabis use increases pain after surgery, study shows

    [ad_1]

    Newswise — NEW ORLEANS — Adults who use cannabis have more pain after surgery than those who don’t use cannabis, according to a study presented at the ANESTHESIOLOGY® 2022 annual meeting

    “Cannabis is the most commonly used illicit drug in the United States and increasingly used as an alternative treatment for chronic pain, but there is limited data that shows how it affects patient outcomes after surgery,” said Elyad Ekrami, M.D., lead author of the study and clinical research fellow of the Outcomes Research Department at Cleveland Clinic’s Anesthesiology Institute. “Our study shows that adults who use cannabis are having more — not less — postoperative pain. Consequently, they have higher opioid consumption after surgery.” 

    Researchers analyzed the records of 34,521 adult patients — 1,681 of them cannabis users — who had elective surgeries at Cleveland Clinic from January 2010 to December 2020. The cannabis users had used the drug within 30 days before surgery, while the other patients had never used cannabis. The patients who used cannabis experienced 14% more pain during the first 24 hours after surgery compared to the patients who never used cannabis. Additionally, patients who used cannabis consumed 7% more opioids after surgery, which the authors note was not statistically significant, but is likely clinically relevant.  

    “The association between cannabis use, pain scores and opioid consumption has been reported before in smaller studies, but they’ve had conflicting results,” Dr. Ekrami added. “Our study has a much larger sample size and does not include patients with chronic pain diagnosis or those who received regional anesthesia, which would have seriously conflicted our results. Furthermore, our study groups were balanced by confounding factors including age, sex, tobacco and other illicit drug use, as well as depression and psychological disorders.”

    Dr. Ekrami noted that additional research is needed to further define cannabis’ effects on surgical outcomes. “Physicians should consider that patients using cannabis may have more pain and require slightly higher doses of opioids after surgery, emphasizing the need to continue exploring a multimodal approach to post-surgical pain control,” he said.  


    THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS
    Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 55,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves. 

    For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/madeforthismoment. Join the ANESTHESIOLOGY® 2022 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES22.

    # # #

     

    [ad_2]

    American Society of Anesthesiologists (ASA)

    Source link

  • Featured Lectures at the 2022 ACG Annual Scientific Meeting and Postgraduate Course

    Featured Lectures at the 2022 ACG Annual Scientific Meeting and Postgraduate Course

    [ad_1]

    Newswise — The featured lectures at the 2022 ACG Annual Scientific Meeting and Postgraduate Course showcase innovative and challenging issues in clinical gastroenterology. This year’s lectures highlight new approaches to inflammatory bowel disease, clinician-led research, optimizing colorectal cancer screening outreach, living with purpose, and the central role of the gut in overall health. All the 2022 featured lectures are at the invitation of ACG President Samir A. Shah, MD, FACG except for The American Journal of Gastroenterology Lecture which was invited by Co-Editors-in-Chief Jasmohan S. Bajaj, MD, MS, FACG and Millie D. Long, MD, MPH, FACG. Access is available for press to view livestreams of the lectures through the ACG 2022 Annual Scientific Meeting virtual platform.

    David Sun Lecture – The Two Most Important Days: Reflections on Lasting Happiness and Living With Purpose
    Sanjiv Chopra, MD
    Saturday, October 22, 10:00 am–10:30 am EDT
    Ways to achieve happiness and live your life’s purpose, no matter the challenges faced along the way. 

    President’s Address – ACG President, Samir A. Shah, MD, FACG, introduced by ACG President-Elect Daniel J. Pambianco, MD, FACG
    Monday, October 24, 9:00 am–9:30 am EDT

    The American Journal of Gastroenterology Lecture – The Transformative Power of Research Carried Out by Busy Clinicians
    Patrick S. Kamath, MD
    Monday, October 24, 3:05 pm–3:35 pm EDT
    How clinicians can participate in research that moves the fields of gastroenterology and hepatology forward.

    Edward Berk Distinguished Lecture – The Promise and Progress of New Approaches to Treating the Inflammatory Bowel Diseases
    Bruce E. Sands, MD, MS, FACG
    Tuesday, October 25, 10:05 am–10:30 am EDT
    Efficacy and safety of newer agents for IBD, and the potential for combination therapy and precision medicine approaches to treat Crohn’s disease and ulcerative colitis. 

    Emily Couric Memorial Lecture – Colon Cancer Screening: What Do We Need to Build and Who Will Come?
    Aasma Shaukat, MD, MPH, FACG
    Tuesday, October 25, 4:30 pm–5:00 pm EDT
    Current colon cancer screening tests and strategies to increase screening uptake in all populations. 

    David Y. Graham Lecture – Why Do All Diseases Start in the Gut?
    Emeran A. Mayer, MD
    Wednesday, October 26, 10:20 am–10:50 am EDT
    A better understanding of how the gut connectome translates microbial signals into health and disease.

     

    About the American College of Gastroenterology
    Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of over 17,000 individuals from 86 countries. The College’s vision is to be the preeminent professional organization that champions the prevention, diagnosis, and treatment of digestive disorders, serving as a beacon to guide the delivery of the highest quality, compassionate, and evidence-based patient care. The mission of the College is to enhance the ability of our members to provide world class care to patients with digestive disorders and advance the profession through excellence and innovation based upon the pillars of Patient Care, Education, Scientific Investigation, Advocacy and Practice Management. www.gi.org

    Visit the ACG Website Media & Press section for all news, featured research, and expert insights related to the ACG 2022 Annual Scientific Meeting and Postgraduate Course. Follow ACG on Twitter, Facebook, LinkedIn, and Instagram, and share your live updates using #ACG2022.

    [ad_2]

    American College of Gastroenterology (ACG)

    Source link

  • New Clinical Advances in Gastroenterology Presented at the American College of Gastroenterology’s 87th Annual Scientific Meeting

    New Clinical Advances in Gastroenterology Presented at the American College of Gastroenterology’s 87th Annual Scientific Meeting

    [ad_1]

    Newswise — Gastroenterologists and other health care professionals will convene at the Charlotte Convention Center in Charlotte, NC, for the premier clinical gastroenterology event—the American College of Gastroenterology’s 87th Annual Scientific Meeting and Postgraduate Course (ACG 2022) to review the latest scientific advances in gastrointestinal (GI) research, treatment of digestive diseases and clinical practice management.

    This year’s scientific presentations reveal significant findings and innovative technologies for the prevention, diagnosis and treatment of digestive diseases and serious GI-related health issues, including inflammatory bowel disease, bariatric surgery, colorectal cancer screening and prevention, liver disease, gastroesophageal reflux disease (GERD), GI bleeding, Barrett’s esophagus, as well as irritable bowel syndrome.

    • Can digital tools help physicians improve colonoscopy adherence rates?
    • What racial/ethnic disparities exist in the use of certain IBD medications?
    • Are pregnancy complications more likely among patients who have had bariatric surgery or took biologic medications?
    • Can virtual reality therapy help improve functional dyspepsia?
    • How has America’s fast-food fixation affected our liver health?
    • How can physicians combat health misinformation their patients find on social media?

    These are some of the intriguing clinical questions answered in the Newsworthy Abstracts selected by the ACG Public Relations Committee, with additional perspective on findings and explanation of what the clinical science means for patients provided by authors. Following the links below, reporters can explore these Newsworthy Abstracts and Author Insights and connect with these researchers for media stories. 

    Please note that all research presented at ACG 2022 is strictly embargoed until Sunday, October 23, 2022, at 12:00 pm Eastern Daylight Time.

    Helpful Links for Media Visit Press Info ACG Annual Scientific Meeting page of gi.org
    Explore ACG’s Press Room logistics, press releases, media advisories and links to author insights, commentary, and perspective on noteworthy clinical findings in gastroenterology and hepatology presented at the ACG 2022 Annual Scientific Meeting.
    [https://gi.org/media/press-info-scientific-meeting]

    Newsworthy Abstracts and Author Insights
    Nominated by the ACG Public Relations Committee, this group of abstracts features scientific findings that are innovative, noteworthy for the lay reader, relevant to those who suffer from common GI problems, and which represent a significant advancement in the diagnosis and treatment of GI diseases. The Committee aims to identify novel and thought-provoking abstracts which reinforce key public health messages, such as the importance of CRC screening, particularly for minority and at-risk populations, or which feature common GI problems in a new way.
    [https://gi.org/media/press-info-scientific-meeting/featured-science]  

    Featured Lectures
    Learn more about the featured lectures by renowned experts which will showcase innovative and challenging issues in clinical gastroenterology at ACG 2022
    [https://gi.org/2022/10/17/featured-lectures-at-acg-2022] 

    Navigating the Abstracts

    ACG 2022 Abstract Guide
    Look at pages 4-7 for the Abstract Award recipients. Look at pages 8-12 for the Presidential Poster Award recipients. ACG’s Presidential Posters are highly meritorious projects selected by the ACG Educational Affairs Committee. 

    Conference Platform
    Tip: Search all of the abstracts on the ACG 2022 Conference Platform:
    [https://www.eventscribe.net/2022/ACG2022/index.asp]

    • General Search: use the search bar at the top of the page. This search will pull any and every instance of an entered name or keyword(s).
    • Oral Papers: On the left sidebar, select “Presentations” and “Browse by Oral Abstracts.” The search will pull in all of the oral abstracts.
    • Posters: select the “Posters” option and in the new window that opens, browse by title, category (organ system), presenter, number, day and session, or award recipients using the left sidebar. Note: the ePoster Hall with final visual posters will open on Sunday, October 23, at 12pm ET.

    Media Interview Requests
    Press room and video recording facilities will be available on site at the Charlotte Convention Center. To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org. From Sunday, October 23, to Wednesday, October 26, in the ACG Press Room (W205 at the Charlotte Convention Center in Charlotte, NC). 

    About the American College of Gastroenterology
    Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of over 17,000 individuals from 86 countries. The College’s vision is to be the preeminent professional organization that champions the prevention, diagnosis, and treatment of digestive disorders, serving as a beacon to guide the delivery of the highest quality, compassionate, and evidence-based patient care. The mission of the College is to enhance the ability of our members to provide world class care to patients with digestive disorders and advance the profession through excellence and innovation based upon the pillars of Patient Care, Education, Scientific Investigation, Advocacy and Practice Management. www.gi.org

    Visit the ACG Website Media & Press section for all news, featured research, and expert insights related to the ACG 2022 Annual Scientific Meeting and Postgraduate Course. Follow ACG on Twitter, Facebook, LinkedIn, and Instagram, and share your live updates using #ACG2022.

    [ad_2]

    American College of Gastroenterology (ACG)

    Source link

  • Radiation Therapy for High-Risk, Asymptomatic Bone Metastases May Prevent Pain and Prolong Life

    Radiation Therapy for High-Risk, Asymptomatic Bone Metastases May Prevent Pain and Prolong Life

    [ad_1]

    Newswise — SAN ANTONIO, October 23, 2022 — Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple sites, a phase II clinical trial suggests. Results of the multicenter, randomized trial (NCT03523351) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

    The clinical trial findings suggest radiation oncologists may play a valuable role in treating widespread bone metastases even in the absence of symptoms. Palliative radiation has historically focused on reducing existing pain and other symptoms when a patient’s cancer is no longer considered curable. Investigators hoped to show that painful complications could be prevented by treating asymptomatic bone metastases with radiation and were surprised to find the benefits may extend beyond comfort.

    “It’s thought-provoking that radiation to prevent pain could potentially prolong life,” said Erin F. Gillespie, MD, lead author of the study and a radiation oncologist at Memorial Sloan Kettering Cancer Center in New York. “It suggests that treating to cure the cancer is not the only thing that can help people live longer.”

    The study arose from the observation that many patients hospitalized for painful bone metastases have evidence of these lesions on imaging scans several months earlier, Dr. Gillespie said. Although external beam radiation therapy is standard-of-care for painful lesions, it has not been used for asymptomatic ones outside of the oligometastatic setting; generally, patients remain on systemic therapy until lesions become symptomatic. Dr. Gillespie and her colleagues wanted to determine “if and when we might intervene before these symptoms occur to prevent hospitalizations and debility from cancer.”

    For the study, researchers identified 78 adults with a metastatic solid tumor malignancy and more than five metastatic lesions, including at least one asymptomatic high-risk bone lesion. Whether a lesion was high-risk was determined by its size (if it was 2 centimeters or more in diameter); its location in the junctional spine; whether it involved the hip or sacroiliac joint; or if it was in one of the long bones of the body, such as those found in arms and legs. Between all enrolled patients, there were a cumulative 122 bone metastases.

    Among study participants, the most common types of primary cancer were lung (27%), breast (24%) and prostate (22%). Participants were randomly assigned to receive standard treatment, which could include systemic treatment (such as chemotherapy or targeted agents) or observation, with or without radiation therapy to treat all of their high-risk bone metastases. Radiation doses varied but were typically low (i.e., not ablative). All patients were followed for at least 12 months or until they succumbed to their disease.

    The primary endpoint was to determine whether treating asymptomatic lesions could prevent skeletal-related events (SREs) – a common and often painful and debilitating complication of bone metastases. SREs include pain, fractures and compression of the spinal cord that requires surgery or radiation. They can contribute to a higher risk of death and higher health care costs.

    Researchers found that treating the asymptomatic lesions with radiation reduced the number SREs and SRE-related hospitalizations and extended overall survival, compared to people who received no radiation. At the end of one year, for patients on the radiation arm, SREs occurred in 1 of 62 lesions (1.6%), compared to 14 of 49 lesions (29%) for those receiving standard care (p<0.001). Significantly fewer patients in the radiation arm were hospitalized for SREs (0 vs. 4, p=0.045).

    After a median 2.4 years of follow-up, overall survival was significantly longer for patients who received radiation therapy, compared to those who did not (hazard ratio 0.50, 95% confidence interval 0.28-0.91, p=0.02). Median overall survival was 1.1 years for the 11 patients who experienced an SRE, compared to 1.5 years for the 67 patients who had no SREs.

    After the first three months, patients in the radiation arm reported less pain than those in the standard care arm (p<0.05), a trend that continued but was no longer statistically significant for the remainder of the study. There were no significant differences in quality of life between the two arms at any point in the study.

    Though it was not in the initial study design, Dr. Gillespie said the team performed an unplanned analysis of which lesions were most likely to cause SREs. While they expected to find those in the long bones might cause more fractures and pain, they found it was metastases in the spine that were most likely to cause subsequent pain, cord compression or fracture. However, the numbers are small and will require further evaluation to confirm.

    Treating those lesions with “even low doses of radiation seemed adequate to prevent the lesion from progressing and causing problems,” Dr. Gillespie said.

    Dr. Gillespie emphasized that because of the study’s small size, its findings, while hypothesis-generating, were not definitive and a larger study is needed to replicate and expand on these analyses. “Our trial results add to a growing field of study examining the potential of early supportive care, but they still need to be confirmed in a larger phase III trial,” she explained.

    She also said future research should seek to answer questions such as: “Does this apply to someone early in the course of their metastatic disease who may not have any symptomatic lesions? At what point would they benefit from intervention with radiation? There are many patients with multiple sites of metastases, but how do we identify those lesions that are most likely to become problematic?”

    “And, once we confirm this is the right thing to do,” she said, “how do we ensure patients who might benefit get access to this treatment?”

    ###

    Attribution to the American Society for Radiation Oncology (ASTRO) Annual Meeting is requested in all coverage. View the meeting press kit at www.astro.org/annualmeetingpress.

    See this study presented:

    • Prophylactic radiation therapy versus standard-of-care for patients with high-risk, asymptomatic bone metastases: A multicenter, randomized phase II trial (Abstract LBA 04)
    • News Briefing: Tuesday, October 25, 9:00 a.m. Central time. Details here.
    • Scientific Presentation: Clinical Trials Session, Sunday, October 23, 10:40 a.m. Central time, Henry B. Gonzalez Convention Center. Details here; email [email protected] for access.

     

    ABOUT ASTRO

    The American Society for Radiation Oncology (ASTRO) is the largest radiation oncology society in the world, with nearly 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and media center and follow us on social media.

     

    [ad_2]

    American Society for Radiation Oncology (ASTRO)

    Source link